Biohit Oyj (LTS:0DRP) Stock Based Compensation: €0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0DRP Biohit Oyj LTS:0DRP
77 GF Score
Price €2.74
GF Value €2.71
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Biohit Oyj Stock Based Compensation?

Biohit Oyj LTS:0DRP -3.18% 77 Stock Based Compensation is €0.00 Mil as of Dec. 2025. GuruFocus rates LTS:0DRP with a GF Score™ of 77/100 and a GF Value™ of €2.71 (Fairly Valued). The stock has 4 warning signs investors should review.

Biohit Oyj's Stock Based Compensation for the six months ended in Dec. 2025 was €0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Biohit Oyj Stock Based Compensation Related Terms

Biohit Oyj Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Biohit Oyj's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biohit Oyj Stock Based Compensation Chart

Biohit Oyj Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biohit Oyj Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0DRP
77GF Score
Biohit Oyj LTS:0DRP
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biohit Oyj Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

What does a Stock Based Compensation of €0.00 Mil mean?
Biohit Oyj (LTS:0DRP) has a Stock Based Compensation of €0.00 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Biohit Oyj and its competitors.
Is Biohit Oyj's Stock Based Compensation too high?
Biohit Oyj's current Stock Based Compensation is €0.00 Mil. Overall, Biohit Oyj has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's Stock Based Compensation compare to ABT and SYK?
Biohit Oyj's Stock Based Compensation of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Biohit Oyj and its competitors. Biohit Oyj's current Stock Based Compensation is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.71, compared to a current price of €2.74 — trading 1.1% above its estimated fair value. The current Stock Based Compensation is €0.00 Mil. Biohit Oyj's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current Stock Based Compensation is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?

Based on GuruFocus' analysis, Biohit Oyj stock appears to be overvalued. The current stock price of €2.74 is trading 1.1% above its estimated GF Value™ of €2.71. GuruFocus considers Biohit Oyj to be Fairly Valued.

Key valuation signals for LTS:0DRP:

  • Stock Based Compensation: €0.00 Mil
  • GF Value™: €2.71 vs. price of €2.74 (1.1% above fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biohit Oyj Business Description

Other Exchanges BIOBV:Finland
Address Laippatie 1, Helsinki, FIN, 00880
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
77GF Score

Get the complete analysis for LTS:0DRP

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.74
Price
€2.71
GF Value